NO970783L - Procedure for preventing endometrial cancer - Google Patents
Procedure for preventing endometrial cancerInfo
- Publication number
- NO970783L NO970783L NO970783A NO970783A NO970783L NO 970783 L NO970783 L NO 970783L NO 970783 A NO970783 A NO 970783A NO 970783 A NO970783 A NO 970783A NO 970783 L NO970783 L NO 970783L
- Authority
- NO
- Norway
- Prior art keywords
- endometrial cancer
- procedure
- preventing
- preventing endometrial
- hexamethylenimino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Fremgangsmåte for å hindre endometrialkreft ^-^^...JX&i^i¿^ (D i -(Ci-C,.al)cyl) (a) 0 II -c-xr (b) Det er beskrevet en fremgangsmåte for inhibering av endometrialkreft som iimbefatter at det til et menneske som har behov for dette administreres en effektiv mengde av en forbindelse av formel (I), hvor R^ og r3 uavhengig av hverandre er hydrogen, -CH3, (a) eller (b), hvor Ar er evenUielt substituert fenyl; r2 er valgt fra gruppen bestående av pyrrolidin, heksametylenimino eller piperidino; eller et farmaseytisk akseptabelt salt eller solvat derav.Procedure for Preventing Endometrial Cancer ^ - ^^ ... JX & i ^ i¿ ^ (D i - (Ci-C, al) cyl) (a) 0 II of endometrial cancer which includes administering to a human in need thereof an effective amount of a compound of formula (I) wherein R 1 and R 3 are independently hydrogen, -CH 3 Ar is optionally substituted phenyl; r 2 is selected from the group consisting of pyrrolidine, hexamethylenimino or piperidino; or a pharmaceutically acceptable salt or solvate thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29385394A | 1994-08-22 | 1994-08-22 | |
PCT/US1995/010651 WO1996005833A1 (en) | 1994-08-22 | 1995-08-21 | Methods of inhibiting endometrial cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO970783D0 NO970783D0 (en) | 1997-02-20 |
NO970783L true NO970783L (en) | 1997-02-20 |
Family
ID=23130867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO970783A NO970783L (en) | 1994-08-22 | 1997-02-20 | Procedure for preventing endometrial cancer |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0777476A4 (en) |
JP (1) | JPH10504824A (en) |
KR (1) | KR970705387A (en) |
AU (1) | AU688112B2 (en) |
CA (1) | CA2198119A1 (en) |
CZ (1) | CZ51897A3 (en) |
FI (1) | FI970717A0 (en) |
HU (1) | HUT76890A (en) |
IL (1) | IL115022A (en) |
MX (1) | MX9701327A (en) |
MY (1) | MY113757A (en) |
NO (1) | NO970783L (en) |
NZ (1) | NZ292017A (en) |
RU (1) | RU2161964C2 (en) |
TW (1) | TW404834B (en) |
WO (1) | WO1996005833A1 (en) |
ZA (1) | ZA956994B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
KR20160066490A (en) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | Heterocyclic derivatives and use thereof |
CN115825414B (en) * | 2023-01-09 | 2023-04-25 | 中国医学科学院北京协和医院 | Blood or urine metabolic marker and application thereof in endometrial cancer early screening |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
JP3157882B2 (en) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | New benzothiophene derivatives |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
AU6556194A (en) * | 1993-04-07 | 1994-10-24 | Ligand Pharmaceuticals Incorporated | Method for screening for receptor agonists |
ATE220323T1 (en) * | 1993-10-15 | 2002-07-15 | Lilly Co Eli | METHOD OF TREATING RESISTANT NEOPLASMS |
AU706953B2 (en) * | 1994-08-22 | 1999-07-01 | Eli Lilly And Company | Methods of inhibiting primary endometrial hyperplasia |
US5843964A (en) * | 1994-09-22 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting endometrial mitoses |
-
1995
- 1995-08-21 RU RU97104160/14A patent/RU2161964C2/en active
- 1995-08-21 TW TW084108700A patent/TW404834B/en not_active IP Right Cessation
- 1995-08-21 CA CA002198119A patent/CA2198119A1/en not_active Abandoned
- 1995-08-21 NZ NZ292017A patent/NZ292017A/en unknown
- 1995-08-21 CZ CZ97518A patent/CZ51897A3/en unknown
- 1995-08-21 AU AU33700/95A patent/AU688112B2/en not_active Ceased
- 1995-08-21 MY MYPI95002449A patent/MY113757A/en unknown
- 1995-08-21 JP JP8508265A patent/JPH10504824A/en active Pending
- 1995-08-21 ZA ZA9506994A patent/ZA956994B/en unknown
- 1995-08-21 WO PCT/US1995/010651 patent/WO1996005833A1/en not_active Application Discontinuation
- 1995-08-21 KR KR1019970701095A patent/KR970705387A/en not_active Application Discontinuation
- 1995-08-21 MX MX9701327A patent/MX9701327A/en unknown
- 1995-08-21 EP EP95930243A patent/EP0777476A4/en not_active Withdrawn
- 1995-08-21 HU HU9701499A patent/HUT76890A/en unknown
- 1995-08-21 IL IL11502295A patent/IL115022A/en not_active IP Right Cessation
-
1997
- 1997-02-20 NO NO970783A patent/NO970783L/en not_active Application Discontinuation
- 1997-02-20 FI FI970717A patent/FI970717A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0777476A1 (en) | 1997-06-11 |
KR970705387A (en) | 1997-10-09 |
IL115022A (en) | 2000-07-31 |
HUT76890A (en) | 1997-12-29 |
NO970783D0 (en) | 1997-02-20 |
IL115022A0 (en) | 1998-06-15 |
ZA956994B (en) | 1997-02-21 |
TW404834B (en) | 2000-09-11 |
CZ51897A3 (en) | 1997-06-11 |
AU688112B2 (en) | 1998-03-05 |
AU3370095A (en) | 1996-03-14 |
FI970717A (en) | 1997-02-20 |
WO1996005833A1 (en) | 1996-02-29 |
CA2198119A1 (en) | 1996-02-29 |
MY113757A (en) | 2002-05-31 |
NZ292017A (en) | 2000-07-28 |
MX9701327A (en) | 1997-05-31 |
FI970717A0 (en) | 1997-02-20 |
RU2161964C2 (en) | 2001-01-20 |
EP0777476A4 (en) | 1999-06-23 |
JPH10504824A (en) | 1998-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO971520L (en) | Method of inhibiting conditions associated with neuropeptide Y | |
NO944928L (en) | Methods for inhibiting Alzheimer's disease | |
NO973635L (en) | Method of inhibiting cell-cell adhesion | |
UA26930C2 (en) | MEANS FOR DEFINITION OF ECHOMETRIOSIS | |
DK0659417T3 (en) | Methods for inhibiting dysfunctional uterine bleeding | |
NO944925L (en) | Steps to increase libido in post-menopausal women | |
NO944933L (en) | Procedure for inhibiting disease states of the breast | |
NO970786L (en) | Procedure for inhibiting bone degradation | |
NO944924L (en) | Procedures for inhibiting Turner's syndrome | |
NO975580L (en) | Method of inhibiting melanoma | |
NO970783L (en) | Procedure for preventing endometrial cancer | |
NO973367L (en) | Method of inhibiting environmental estrogen | |
NO981578L (en) | Method of inhibiting plasminogen activator inhibitor I | |
NO973609L (en) | Method of inhibiting the effects of IL-6 | |
NO971794L (en) | Method of inhibiting states associated with bradykinin | |
NO971029L (en) | Methods for inhibiting endometrial metoses | |
NO973103L (en) | Method for inhibiting growth hormone effects | |
NO970787D0 (en) | Procedure for inhibition of primary endometrial hyperplasia | |
NO983452L (en) | Procedures for Inhibiting Musculoaponeurotic Fibromatosis (Desmoid Tumors) | |
NO983451L (en) | Procedure for inhibiting colon tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |